Tresiba® (insulin degludec) (NN1250)

:Type 1 and 2 diabetes
:Filed for registration

A new-generation once-daily basal insulin analogue with a duration of action beyond 42 hours and a flat and stable action profile that compared with insulin glargine reduces the rate of
hypoglycaemia and increases dosing flexibility when needed. Launched in the EU, Japan and other markets. Additional data required by the US FDA are being generated for the planned
resubmission.

Company announcements
Novo Nordisk increased operating profit in local currencies by 13% in 2014 (30 Jan 2015)
Increased operating profit in local currencies by 11% in the first nine months of 2014 (30 Oct 2014)
Novo Nordisk increased operating profit in local currencies by 12% in the first six months of 2014 (07 Aug 2014)
Read more company announcements

Press releases
Switzerland first country to launch Xultophy® (IDegLira) (19 Jan 2015)
Tresiba® receives positive opinion from CHMP for treatment of children with diabetes (19 Dec 2014)
New Xultophy® (IDegLira) data show rapid and predictable glycaemic improvements in people with type 2 diabetes (19 Sep 2014)
Read more press releases

Scientific abstracts
Advances in Therapy (2013)
Biochemistry (2013)
Clinical Drug Investigation (2013)
Read more scientific abstracts

You can search for more clinical trials on http://clinicaltrials.gov
  •